PR Newswire (Tue, 7:50AM)
Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
451 people get ECTE articles and Market Currents by email alert.
Get email alerts on ECTE »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Thu, 7:50AM)
-
PR Newswire (May 10, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 15, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 15, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Dec 27, 2012)
-
PR Newswire (Dec 27, 2012)
-
PR Newswire (Dec 26, 2012)
-
PR Newswire (Dec 20, 2012)
-
PR Newswire (Dec 20, 2012)
To learn more about Seeking Alpha Pro, click here.
-
20 Micro-Cap Stocks Being Snapped Up By Hedge FundsKapitall • Thu, Dec 15, 2011
-
PR Newswire (Thu, 7:50AM)
-
PR Newswire (May 10, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 15, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Feb 6, 2013)
-
at MarketWatch.com (Feb 1, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 15, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Dec 27, 2012)
-
PR Newswire (Dec 27, 2012)
-
PR Newswire (Dec 26, 2012)
-
PR Newswire (Dec 20, 2012)
-
PR Newswire (Dec 20, 2012)
ECTE vs. ETF Alternatives
Company Description
Currently, there's no company description for ECTE.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 21, 10:27 AM Echo Therapeutics (ECTE +2%) settles in following in 12% jump after the opening bell on the company's announcement that the clinical trial of its Symphony CGM System has received Institutional Review Board approval. The board approval enables the Symphony system, which is a non-invasive, wireless, transdermal continuous glucose monitoring platform, to offically start clinical evaluations for a European CE Mark. Comment! [Healthcare]
- Friday, May 10, 7:55 AM Echo Therapeutics (ECTE): Q1 EPS of -$0.13 misses by $0.03. Revenue of $22.56M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, March 12, 11:03 AM Echo Therapeutics (ECTE +6.7%) says it's been granted a patent for its Prelude SkinPrep System, a device and method for preparing the skin to allow for analyte extraction or drug delivery. The system is a component of the company's Symphony GSM System, a non-invasive glucose monitoring system. Comment! [Healthcare, On the Move]
- Friday, February 1, 4:02 PM Echo Therapeutics (ECTE -29.4%) gets slammed today, after it prices its previously announced 13.3M share offering at $0.75 apiece, a 35% discount to Thursday's closing price. 1 Comment [Healthcare, On the Move]
-
Friday, February 1, 12:45 PM
Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move] -
Friday, February 1, 9:10 AM
Premarket gainers: ADNC +30%. TSYS +15%. RAD +9%. CTRP +8%. EDAP +7%. ALU +6%. DELL +6%. VVUS +5%. PRGO +5%.
Losers: ECTE -35%. OTT -23%. LTM -16%. SDR -11%. OCZ -8%. CLSN -7%. ALKS -7%. NMM -6%. TLAB -5%. Comment! [On the Move] - Thursday, January 31, 6:48 PM Echo Therapeutics (ECTE) announces a secondary offering, but no details of the size or terms were given. Aegis Capital is acting as the sole book-running manager for the offering. Shares -7.8% AH. Comment! [Healthcare, On the Move]
-
Friday, January 25, 9:10 AM
Premarket gainers: INFA +10%. TPX +10%. ECTE +9%. OSK +8%. STP +6%. THLD +7%. SNE +6%.
Losers: SCSS -15%. BGMD -15%. EGHT -10%. SFL -8%.
1 Comment [On the Move] - Tuesday, January 22, 2:04 PM Echo Therapeutics (ECTE -6%) slips despite presenting positive results from an expanded analysis of data collected from clinical studies of its Symphony tCGM glucose monitoring system in critically ill patients at Tufts Medical Center in Boston. The data was presented during over the weekend at the Society of Critical Care Medicine's 42nd Critical Care Congress. Comment! [Healthcare, On the Move]
-
Friday, December 21, 2012, 12:45 PM
Midday top 10 gainers: HALO +27%. CEMI +24%. ASCA +20%. FCFC +18%. PNK +17%. ABCD +14%. ATAI +12%. BONA +11%. WWAY +9%. IKAN +9%.
Midday top 10 Losers: CT -52%. ALX -26%. RIMM -21%. EDMC -19%. MSON -17%. ECTE -17%. HLF -14%. OPXA -13%. MHH -12%. AMPL -11%. 3 Comments [On the Move] - Friday, December 21, 2012, 12:43 PM Echo Therapeutics (ECTE -17%) trades lower today after the company priced its previously announced 3.2M secondary offering at $0.95 per share, an 18% discount to yesterday's close. Aegis Capital is the sole book-running manager for the offering. Comment! [Healthcare, On the Move]
-
Friday, December 21, 2012, 9:10 AM
Premarket gainers: HALO +19%. CEMI +17%. ASCA +17%. APPY +14%. RHT +5%. PNK +5%. SHP +5%.
Losers: ECTE -18%. RIMM -14%. ALU -7%. 1 Comment [On the Move] -
Wednesday, October 10, 2012, 12:45 PM
Midday top 10 gainers: CLNT +28%. TRLG +23%. AUQ +17%. KGN +15%. PBM +14%. OTT +12%. BLIN +19%. KID +12%. VVTV +12%. ECTE +9%.
Top 10 Losers: OCZ -40%. ACW -32%. FOE -24%. GLUU -14%. BSET -11%. HELE -10%. BSDM -10%. UPI -10%. AMRN -10%. TZYM -9%. Comment! [On the Move] - Thursday, June 14, 2012, 7:03 AM Russell Investments is reshuffling the Russell Microcap Index (IWC) on June 25. New additions to the index include CytRx (CYTR), Synergy Resources (SYRG) and Echo Therapeutics (ECTE). The full list of changes (here) will be finalized June 22. Comment!
-
- View all 1 replies
-
Systembolaget: Glad I exited yesterday morning @ €2,90. Today @ €2,72 NOK is back to where it was mid November 2012.
-
The Illogical Investor
Echo Therapeutics ticker ECTE. Announces positive results from trial of non invasive glucose monitoring system and direct capital raise - View all 0 replies
-
David Zanoni
ECTE is trading in a channel approx. between $3 & $4 - it is now at the low end of the channel at $2.92 - View all 0 replies
LATEST REPLIES

